Molecular pathological Diagnostics

A major challenge in view of the increasing knowledge about therapy-relevant molecular changes in lung cancer cells is the development of a high-quality molecular diagnostics, covering all these driver mutations quickly and accurately. At the Institute of Pathology at the University Hospital of Cologne a molecular diagnostic platform has been set up at the Network Genomic Medicine for this purpose covering all known driver mutations. This includes, among others, mutations in the genes EGFR, KRAS, BRAF, PIK3CA, HER2, p53, MET and DDR2, translocations in ALK, RET, ROS1 and amplifications in HER2, MET and FGFR1. The list of examined molecular changes will be updated regularly based on current research findings.
Netzwerk Genomische Medizin (NGM) Lungenkrebs

As part of the Network Genomic Medicine this diagnostics is provided to patients and cooperation partners regardless of residence or therapeutic location. By means of an integrated care contract reimbursement is guaranteed beyond the regular budget of treatment in a hospital or as an outpatient. The participation of an attending physician and the patient in the integrated care is a prerequisite for this. Ince 2012, as the first group in Europe, we have offered a comprehensive analysis with a multiplex test in combination with highly sensitive deep sequencing which also detects rare gene mutations in the smallest tissue samples reliably. For that, multiple techniques are used on routinely formalin-fixed and paraffin-embedded samples, such as Next Generation Sequencing (NGS), immunohistochemical detection of gene expression and fluorescence in situ hybridization (FISH).

Last update: 07. March 2016 , 12:25

Molecular diagnostics

As the first group in Europe, the Network Genomic Medicine has offered a comprehensive analysis of tumor material since 2012. By means of a multiplex-test in combination with highly sensitive deep sequencing even rare gene mutations in the smallest tissue samples are detected reliably

Diagnostics
w

Second opinion

Do you have questions about your disease or your current therapy? Or maybe you would like to know if for you a personalized treatment approach or immunotherapy might be considered. Please feel free to contact us!

Second Opinion
n

Clinical trials

At the Network Genomic Medicine we try to offer an appropriate clinical trial testing a new drug to all our patients who have a detected mutation, for which there has no drug been approved for treatment yet. For that we work closely together with the Lung Cancer Group Cologne.

Trials